Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

A kind of tenofovir preparation method suitable for industrialized production

A technology of tenofovir and its products, which is applied in the field of drug synthesis, can solve the problems affecting the yield of industrialized large-scale production process, demanding filtering equipment, and hindering the crystallization of tenofovir, so as to achieve convenient industrial production, easy operation and reproducibility good sex effect

Active Publication Date: 2015-09-30
FUJIAN COSUNTER PHARMA CO LTD
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The (R)-9-[2-(diethylphosphonomethoxy) propyl group] adenine hydrolysis step in the above-mentioned technical route mainly has the following problems in the actual production process: Precipitation is purified to obtain the method for tenofovir, the amount of added water is too little (only 3 times), this makes the reaction solution extremely viscous, which hinders the crystallization of tenofovir, and the crystals of tenofovir obtained are too fine and less in amount, which makes it very difficult to filter and requires strict filtering equipment; moreover, the operating temperature Slightly higher (≥5°C), the phenomenon that the precipitate will be redissolved in the reaction mixture solution will seriously affect the yield of the industrialized large-scale production process. At the same time, the filtration process requires low temperature operation, which virtually increases the process cost; The process is to adjust the pH to about 0.9-1.3 at 35-50°C while maintaining the temperature at about 45°C, add PMPA seeds to the mixture, and then adjust the pH to about 2.6-3.0 while maintaining the temperature at about 35-50 ℃, under slow to moderate stirring without splashing the contents, take about 3-20 hours to cool the solution to about 35 ℃ and the product begins to precipitate
In actual production and application, it is found that the above method takes too long at the heating temperature and is unnecessary. It is often impossible to cause crystallization when the seed crystal is put in at 45°C, and the tenofovir product is also often lowered to 35°C after cooling down. Failure to precipitate normally, poor reproducibility in production

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of tenofovir preparation method suitable for industrialized production
  • A kind of tenofovir preparation method suitable for industrialized production
  • A kind of tenofovir preparation method suitable for industrialized production

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0033] Preparation of tenofovir

[0034] Reaction formula:

[0035]

Embodiment 1

[0037] Feed 20kg of (R)-9-[2-(diethylphosphonomethoxy)propyl]adenine and 160L of acetonitrile. Dissolve at 60°C, add 60kg of trimethylbromosilane dropwise, and react under reflux at 80°C. After the reaction was completed, it was filtered, and the filtrate was concentrated. After the concentration is completed, add 160L of water (the amount of water added: (R)-9-[2-(diethylphosphonomethoxy)propyl]adenine=8:1), let the layers stand, and collect the lower liquid . Add 50% sodium hydroxide to adjust the pH value to ≈3.0, use gradient cooling, first cool down to 20°C for crystallization for 4 hours, then cool down to 10°C for 4 hours, then cool down to 0°C for 8 hours, and stir slowly during the process (stirring speed 100r / min, stirring for 5 minutes every hour). The product was suction filtered, dried, and weighed to obtain tenofovir 10.50kg.

Embodiment 2

[0039] Feed 20kg of (R)-9-[2-(diethylphosphonomethoxy)propyl]adenine and 160L of acetonitrile. Dissolve at 60°C, add 60.00kg of bromotrimethylsilane dropwise, and react under reflux at 80°C. After the reaction was completed, it was filtered, and the filtrate was concentrated. After the concentration is completed, add 120L of water (the amount of water added: (R)-9-[2-(diethylphosphonomethoxy)propyl]adenine=6:1), let the layers stand, and collect the lower liquid . Add 50% sodium hydroxide to adjust the pH value to ≈2.5, use gradient cooling, first cool down to 20°C for crystallization for 4 hours, then cool down to 10°C for 8 hours, then cool down to 0°C for 12 hours, and stir slowly during the process (stirring speed 200r / min, stirring for 5 minutes every hour). Suction filtration, dry, weigh, obtain tenofovir 9.73kg.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a tenofovir preparation method suitable for industrialized production. According to the method, tenofovir is obtained through catalyzing and hydrolyzing a raw material intermediate (R)-9-[2-(diethylphosphonomethoxy)propyl]adenine via trimethylbromosilane, wherein the raw material intermediate (R)-9-[2-(diethylphosphonomethoxy)propyl]adenine is obtained through the following steps: firstly, obtaining (R)-9-(2-hydroxypropyl)adenine via the ring-opening condensation of adenine and (R)-epoxypropane under an alkaline condition; secondly, catalyzing the (R)-9-(2-hydroxypropyl)adenine through lithium t-butoxide; thirdly, conducting etherification on the catalyzed (R)-9-(2-hydroxypropyl)adenine and p-benzenesulfonyloxymethyl phosphoric acid diethylester, so as to obtain the (R)-9-[2-(diethylphosphonomethoxy)propyl]adenine. The method is characterized in that purified water of appropriate proportion is added in a mixed product obtained through catalyzing and hydrolyzing the (R)-9-[2-(diethylphosphonomethoxy)propyl] adenine via trimethylbromosilane; the tenofovir is obtained through spontaneous crystallization at an appropriate temperature and cooling rate, as well as at an appropriate stirring speed. According to the invention, the obtained tenofovir product has the characteristics of high yield, strong indissolubility in operation under room temperature, simplicity in filtration and collection due to large particles, short production time, low energy consumption, and the like.

Description

technical field [0001] The invention belongs to the technical field of drug synthesis, in particular to an antiviral drug 9-[(R)-2-[[bis[(isopropoxyacyloxy)methoxy]phosphono]methoxy]propyl ] Synthesis of adenine fumarate intermediate. Background technique [0002] Tenofovir disoproxil fumarate, [Chinese alias] (R)-9-(2-phosphomethoxypropyl) adenine bis(isopropoxycarbonyloxymethyl) ester fumarate, [chemical name 】(R)-[[2-(6-Amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid diisopropoxycarbonyloxymethyl ester fumarate, It is a nucleotide reverse transcriptase inhibitor and a prodrug of tenofovir (PMPA), which is mainly used clinically to treat human immunodeficiency virus (HIV) infection. The structural formula is as follows: [0003] [0004] Chinese patent CN1244200 has reported a kind of synthetic technique of tenofovir disoproxil fumarate: (S)-glycidol is reduced to (R)-1,2-propanediol by catalytic hydrogenation, then reacts with diethyl carbonate to obtain ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07F9/6561
Inventor 林桂坤吴文强马志强苏葳张燕华
Owner FUJIAN COSUNTER PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products